Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., et al. (2012). Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. JOURNAL OF CLINICAL ONCOLOGY, 30(20), 2475-2482 [10.1200/JCO.2011.37.4918].

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

IACOBELLI, SIMONA;
2012-01-01

2012
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/01 - STATISTICA MEDICA
English
Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., et al. (2012). Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. JOURNAL OF CLINICAL ONCOLOGY, 30(20), 2475-2482 [10.1200/JCO.2011.37.4918].
Garderet, L; Iacobelli, S; Moreau, P; Dib, M; Lafon, I; Niederwieser, D; Masszi, T; Fontan, J; Michallet, M; Gratwohl, A; Milone, G; Doyen, C; Pegouri...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Garderet_MMVAR_JCO 2012.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 194.39 kB
Formato Adobe PDF
194.39 kB Adobe PDF Visualizza/Apri
Garderet_MMVAR_JCO editorial May 2012.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 141.79 kB
Formato Adobe PDF
141.79 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/78032
Citazioni
  • ???jsp.display-item.citation.pmc??? 49
  • Scopus 187
  • ???jsp.display-item.citation.isi??? 169
social impact